Ceralasertib plus durvalumab in Ras mutant and Ras wild type advanced non-small cell lung cancer: Two cohorts of the phase II platform National Lung Matrix Trial

Gary Middleton, Richard Buchanan, Joshua Savage, Joe De La Mata Chicharro, Manita Mehmi, Rosanna J. Wilkins, Richard D. W. Kelly, Claire Wilson, Aditi Kanhere, Helen L. Robbins, Luke Ames, Alastair Greystoke, Adam Dangoor, Judith Cave, Paul Shaw, Nicola Steele, Katy Clarke, Pooja Bhatnagar, Mary O'Brien, Sanjay Popat, Martin D. Forster, James Spicer, Nicholas Coupe, Sarah Danson, David Gilligan, Dakshinamoorthy Muthukumar, Gillian Price, Yvonne Summers, Elizabeth Toy, Timothy Yap, Charles Swanton, Andrew Beggs, Heather Long, Eva Petermann, Lucinda Billingham

Open source

DOI: 10.1158/1078-0432.ccr-26-1365
Published: 2026-09-09
Container: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-26-1365,
  title = {Ceralasertib plus durvalumab in Ras mutant and Ras wild type advanced non-small cell lung cancer: Two cohorts of the phase II platform National Lung Matrix Trial},
  author = {Gary Middleton and Richard Buchanan and Joshua Savage and Joe De La Mata Chicharro and Manita Mehmi and Rosanna J. Wilkins and Richard D. W. Kelly and Claire Wilson and Aditi Kanhere and Helen L. Robbins and Luke Ames and Alastair Greystoke and Adam Dangoor and Judith Cave and Paul Shaw and Nicola Steele and Katy Clarke and Pooja Bhatnagar and Mary O'Brien and Sanjay Popat and Martin D. Forster and James Spicer and Nicholas Coupe and Sarah Danson and David Gilligan and Dakshinamoorthy Muthukumar and Gillian Price and Yvonne Summers and Elizabeth Toy and Timothy Yap and Charles Swanton and Andrew Beggs and Heather Long and Eva Petermann and Lucinda Billingham},
  year = {2026},
  journal = {Clinical Cancer Research},
  doi = {10.1158/1078-0432.ccr-26-1365},
  url = {https://doi.org/10.1158/1078-0432.ccr-26-1365}
}

RIS

TY  - JOUR
TI  - Ceralasertib plus durvalumab in Ras mutant and Ras wild type advanced non-small cell lung cancer: Two cohorts of the phase II platform National Lung Matrix Trial
AU  - Gary Middleton
AU  - Richard Buchanan
AU  - Joshua Savage
AU  - Joe De La Mata Chicharro
AU  - Manita Mehmi
AU  - Rosanna J. Wilkins
AU  - Richard D. W. Kelly
AU  - Claire Wilson
AU  - Aditi Kanhere
AU  - Helen L. Robbins
AU  - Luke Ames
AU  - Alastair Greystoke
AU  - Adam Dangoor
AU  - Judith Cave
AU  - Paul Shaw
AU  - Nicola Steele
AU  - Katy Clarke
AU  - Pooja Bhatnagar
AU  - Mary O'Brien
AU  - Sanjay Popat
AU  - Martin D. Forster
AU  - James Spicer
AU  - Nicholas Coupe
AU  - Sarah Danson
AU  - David Gilligan
AU  - Dakshinamoorthy Muthukumar
AU  - Gillian Price
AU  - Yvonne Summers
AU  - Elizabeth Toy
AU  - Timothy Yap
AU  - Charles Swanton
AU  - Andrew Beggs
AU  - Heather Long
AU  - Eva Petermann
AU  - Lucinda Billingham
PY  - 2026
JO  - Clinical Cancer Research
DO  - 10.1158/1078-0432.ccr-26-1365
UR  - https://doi.org/10.1158/1078-0432.ccr-26-1365
ER  -

APA

Middleton, G., Buchanan, R., Savage, J., Chicharro, J. D. L. M., Mehmi, M., Wilkins, R. J., Kelly, R. D. W., Wilson, C., Kanhere, A., Robbins, H. L., Ames, L., Greystoke, A., Dangoor, A., Cave, J., Shaw, P., Steele, N., Clarke, K., Bhatnagar, P., O'Brien, M., Popat, S., Forster, M. D., Spicer, J., Coupe, N., Danson, S., Gilligan, D., Muthukumar, D., Price, G., Summers, Y., Toy, E., Yap, T., Swanton, C., Beggs, A., Long, H., Petermann, E., & Billingham, L. (2026). Ceralasertib plus durvalumab in Ras mutant and Ras wild type advanced non-small cell lung cancer: Two cohorts of the phase II platform National Lung Matrix Trial. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-26-1365

Source records

crossref · retrieved 2026-09-26T06:17:20.455Z